Chronic PeriodontitisNCT02195765
Randomized Clinical Trial of Enamel Matrix Derivative: Radiographic Analysis
A study testing enamel matrix derivative and Open flap debridement in people with Chronic Periodontitis, run by University of Sao Paulo at 1 site in Brazil.
Trial summary
This is a split-mouth, double-blind randomized controlled trial. Computerized linear radiographic measurements were used to detect infrabony defects treated with open flap debridement (OFD) or OFD associated with enamel matrix derivative (EMD), after 24 months. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Periodontitis
- What is being tested?
- enamel matrix derivative and Open flap debridement
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 48 participants
- Where
- 1 siteBrazil
- Study dates
- Jun 2002to Oct 2005
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- diagnosis of chronic periodontitis
- presence of at least one pair of interproximal infrabony defects (2-3 walls) adjacent to vital anterior or premolar teeth
- absence of 2 and 3 mobility degrees
- probing pocket depth (PPD)≥ 5mm
- full-mouth plaque score ≤ 20%
- keratinized tissue width of at least 2mm
Who cannot join
- presence of any systemic disease that could interfere with periodontal treatment
- infrabony defects with trans-surgical depth ≤4mm
- antibiotic treatment administered during the last 6 months -
Trial locations and contacts
1 site in 1 country.
Brazil1 site
Faculdade de Odontologia da Universidade de São Paulo (FOUSP)
São Paulo, São Paulo
About this study
Official title: Two-year Randomized Clinical Trial of Enamel Matrix Derivative Treated Infrabony Defects: Radiographic Analysis
This is a split-mouth, double-blind randomized controlled trial. Computerized linear radiographic measurements were used to detect infrabony defects treated with open flap debridement (OFD) or OFD associated with enamel matrix derivative (EMD), after 24 months. Ten patients presenting 2 or more defects were selected (43 defects). An individualized film holder was used to take standardized radiographs at baseline and after 24 months. Images were digitized and used to measure the distances from the cemento-enamel junction (CEJ) to the alveolar crest (AC), CEJ to the bottom of the defect (BD) and infrabony defect angle.
Read the detailed description
This was a split-mouth randomized controlled trial. Patients were recruited among the ones seeking for periodontal treatment at the Post-graduate Clinic of Periodontics using the following inclusion criteria: (1) diagnosis of chronic periodontitis15; (2) presence of at least one pair of interproximal infrabony defects (2-3 walls) adjacent to vital anterior or premolar teeth; (3) absence of 2 and 3 mobility degrees16; (4) probing pocket depth (PPD)≥ 5mm; (5) full-mouth plaque score ≤ 20%17; and (6) keratinized tissue width of at least 2mm. The exclusion criteria were: (1) presence of any systemic disease that could interfere with periodontal treatment; (2) infrabony defects with trans-surgical depth ≤4mm; (3) antibiotic treatment administered during the last 6 months.
The patients participating in the study were volunteers who received and gave informed consent and were included in the study from June to October 2002.
Following initial examination, all patients underwent oral hygiene instruction and full-mouth supra- and sub-gingival scaling and root planning under local anesthesia. Patients were re-evaluated after completion of the initial therapy to determine their response to therapy and to confirm the need for periodontal surgery. Before surgery, for each pair of defects, one defect was randomly assigned to test (EMD) and one to control (OFD) treatment by toss of a coin. Both defects were treated at the same surgical time. When a patient presented with more than one pair of defects, only one pair was treated per day. Following local anesthesia, all sites were treated with reflection of a full thickness mucoperiosteal flap after intra-sulcular incisions. The exposed roots and osseous defects were debrided with hand instruments, and the surgical wound was rinsed with saline.
After that, the flaps of the OFD sites were repositioned and sutured using 5-0 nylon sutures. The EMD sites were dried with non-woven gauze, roots were conditioned with 24% ethylenediaminotetracetic acid (EDTA) gel (pH 6.7) for 2 minutes. The defect was thoroughly rinsed with saline, and EMD gel was applied to the root surfaces according to the manufacturer's instructions. The flaps were then replaced for primary closure and sutured with 5-0 nylon sutures. The sutures were removed after 7 days. All surgeries were performed by the same investigator. All patients were prescribed 0.12% chlorhexidine digluconate and instructed to rinse gently twice a day for 4 weeks. Analgesics were prescribed to be taken as needed, and all patients were seen once a week, for 8 weeks, for professional tooth cleaning. Subsequently, the patients were maintained in a supportive periodontal program (ie, professional tooth cleaning and reinforcement of self-administered oral hygiene measures) at 2-month intervals up to 6-month time and then every 3 months until final examination at 24 months.
Standardized periapical radiographs were taken at baseline evaluation, immediately before surgery and at 24 months follow-up. Individually customized bite blocks employing a reference occlusal stent and film holders were used to obtain reproducible exposed films at each radiographic control. All radiographs were evaluated by a single calibrated examiner, blind to time and treatment.
Analyses of the radiographic outcomes were performed using computerized linear measurements with image analysis software. The radiographs were previously scanned in digital format by a scanner at a resolution of 500dpi/8bits.
The radiographic analysis was based in anatomical landmarks (CEJ, BD and AC) that were identified on the scanned radiographs. All linear measurements were recorded by a blinded, calibrated examiner. The following outcomes were measured at radiographs taken at baseline and after 24 months:
- Distance from the CEJ to the bottom of the defect (BD). The most coronal area where the periodontal ligament maintained an even width was identified to measure the most apical extension of the infrabony defect;
- Distance from the CEJ to the bone crest (BC);
- Infrabony defect angle was defined by two lines that represented the root surface of the involved tooth (CEJ-BD) and the bone defect surface (BD-BC).
The distance from the CEJ to the bottom of the defect (BD) was considered the primary outcome. CEJ-BC and defect angle were secondary outcomes
- Conditions
- Chronic Periodontitis
- Being tested
- enamel matrix derivative, Open flap debridement
- Keywords
- Chronic Periodontitis, Periodontal disease
- Medical subject headings
- Chronic Periodontitis, Periodontal Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
enamel matrix derivativeDrug
Also called Emdogain, Straumann
Open flap debridement associated with enamel matrix derivative
Open flap debridementProcedure or surgery
Open flap debridement
| Study group | Role | What they receive |
|---|---|---|
| enamel matrix derivative | Experimental | Open flap debridement associated with Enamel matrix derivative gel (Emdogain, Straumann) Receives: Drug: enamel matrix derivative; Procedure: Open flap debridement |
| Open flap debridment | Active comparator | Open flap debridement Receives: Procedure: Open flap debridement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Distance from the cemento-enamel junction (CEJ) to the bottom of the defect (BD)
The most coronal area where the periodontal ligament maintained an even width was identified to measure the most apical extension of the infrabony defect
Measured: 24 months
Secondary outcomes (2)
Distance from the CEJ to the bone crest
Measured: 24 months
Infrabony defect angle
Infrabony defect angle was defined by two lines that represented the root surface of the involved tooth (CEJ-BD) and the bone defect surface (BD-BC)
Measured: 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Jul 2014 (estimated)
- Study startJun 2002
- Primary completionOct 2004
- Study completionOct 2005
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Chronic PeriodontitisStudies of the same condition, open and under way.
- More trials run by University of Sao PauloThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 48 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Sao Paulo
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mariana Ragghianti Zangrando, University of Sao Paulo
- Investigators
- Luiz Antonio PA Lima, Associate, Principal investigator, University of Sao Paulo
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02195765
- Sponsor's protocol ID
- EMD24
- Status last verified
- Jul 2014
- First submitted
- 16 Jul 2014
- Last updated
- 21 Jul 2014
- Results posted
- No
- Data monitoring committee
- No
Publications
Chambrone D, Pasin IM, Chambrone L, Pannuti CM, Conde MC, Lima LA. Treatment of infrabony defects with or without enamel matrix proteins: a 24-month follow-up randomized pilot study. Quintessence Int. 2010 Feb;41(2):125-34.
PubMed 20165744Chambrone D, Pasin IM, Conde MC, Panutti C, Carneiro S, Lima LA. Effect of enamel matrix proteins on the treatment of intrabony defects: a split-mouth randomized controlled trial study. Braz Oral Res. 2007 Jul-Sep;21(3):241-6. doi: 10.1590/s1806-83242007000300009.
PubMed 17710290Ragghianti Zangrando MS, Chambrone D, Pasin IM, Conde MC, Pannuti CM, de Lima LA. Two-year randomized clinical trial of enamel matrix derivative treated infrabony defects: radiographic analysis. BMC Oral Health. 2014 Dec 4;14:149. doi: 10.1186/1472-6831-14-149.
PubMed 25475143
Study at a glance
From the registry record, last updated by the sponsor on 21 Jul 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Two-year Randomized Clinical Trial of Enamel Matrix Derivative Treated Infrabony Defects: Radiographic Analysis
- ClinicalTrials.gov ID
- NCT02195765
- Acronym / sponsor ID
- EMD24
- Conditions
- Chronic Periodontitis
- Keywords
- Chronic Periodontitis, Periodontal disease
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 48 participants (actual)
- Lead sponsor
- University of Sao PauloUniversity, hospital or other
- Study start
- Jun 2002
- Primary completion
- Oct 2004 (actual)
- Study completion
- Oct 2005 (actual)
- First posted
- 21 Jul 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a split-mouth, double-blind randomized controlled trial. Computerized linear radiographic measurements were used to detect infrabony defects treated with open flap debridement (OFD) or OFD associated with enamel matrix derivative (EMD), after 24 months. Ten patients presenting 2 or more defects were selected (43 defects). An individualized film holder was used to take standardized radiographs at baseline and after 24 months. Images were digitized and used to measure the distances from the cemento-enamel junction (CEJ) to the alveolar crest (AC), CEJ to the bottom of the defect (BD) and infrabony defect angle.
Detailed description
This was a split-mouth randomized controlled trial. Patients were recruited among the ones seeking for periodontal treatment at the Post-graduate Clinic of Periodontics using the following inclusion criteria: (1) diagnosis of chronic periodontitis15; (2) presence of at least one pair of interproximal infrabony defects (2-3 walls) adjacent to vital anterior or premolar teeth; (3) absence of 2 and 3 mobility degrees16; (4) probing pocket depth (PPD)≥ 5mm; (5) full-mouth plaque score ≤ 20%17; and (6) keratinized tissue width of at least 2mm. The exclusion criteria were: (1) presence of any systemic disease that could interfere with periodontal treatment; (2) infrabony defects with trans-surgical depth ≤4mm; (3) antibiotic treatment administered during the last 6 months.
The patients participating in the study were volunteers who received and gave informed consent and were included in the study from June to October 2002.
Following initial examination, all patients underwent oral hygiene instruction and full-mouth supra- and sub-gingival scaling and root planning under local anesthesia. Patients were re-evaluated after completion of the initial therapy to determine their response to therapy and to confirm the need for periodontal surgery. Before surgery, for each pair of defects, one defect was randomly assigned to test (EMD) and one to control (OFD) treatment by toss of a coin. Both defects were treated at the same surgical time. When a patient presented with more than one pair of defects, only one pair was treated per day. Following local anesthesia, all sites were treated with reflection of a full thickness mucoperiosteal flap after intra-sulcular incisions. The exposed roots and osseous defects were debrided with hand instruments, and the surgical wound was rinsed with saline.
After that, the flaps of the OFD sites were repositioned and sutured using 5-0 nylon sutures. The EMD sites were dried with non-woven gauze, roots were conditioned with 24% ethylenediaminotetracetic acid (EDTA) gel (pH 6.7) for 2 minutes. The defect was thoroughly rinsed with saline, and EMD gel was applied to the root surfaces according to the manufacturer's instructions. The flaps were then replaced for primary closure and sutured with 5-0 nylon sutures. The sutures were removed after 7 days. All surgeries were performed by the same investigator. All patients were prescribed 0.12% chlorhexidine digluconate and instructed to rinse gently twice a day for 4 weeks. Analgesics were prescribed to be taken as needed, and all patients were seen once a week, for 8 weeks, for professional tooth cleaning. Subsequently, the patients were maintained in a supportive periodontal program (ie, professional tooth cleaning and reinforcement of self-administered oral hygiene measures) at 2-month intervals up to 6-month time and then every 3 months until final examination at 24 months.
Standardized periapical radiographs were taken at baseline evaluation, immediately before surgery and at 24 months follow-up. Individually customized bite blocks employing a reference occlusal stent and film holders were used to obtain reproducible exposed films at each radiographic control. All radiographs were evaluated by a single calibrated examiner, blind to time and treatment.
Analyses of the radiographic outcomes were performed using computerized linear measurements with image analysis software. The radiographs were previously scanned in digital format by a scanner at a resolution of 500dpi/8bits.
The radiographic analysis was based in anatomical landmarks (CEJ, BD and AC) that were identified on the scanned radiographs. All linear measurements were recorded by a blinded, calibrated examiner. The following outcomes were measured at radiographs taken at baseline and after 24 months:
- Distance from the CEJ to the bottom of the defect (BD). The most coronal area where the periodontal ligament maintained an even width was identified to measure the most apical extension of the infrabony defect;
- Distance from the CEJ to the bone crest (BC);
- Infrabony defect angle was defined by two lines that represented the root surface of the involved tooth (CEJ-BD) and the bone defect surface (BD-BC).
The distance from the CEJ to the bottom of the defect (BD) was considered the primary outcome. CEJ-BC and defect angle were secondary outcomes
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| enamel matrix derivative | Experimental | Drug: enamel matrix derivative, Procedure: Open flap debridementOpen flap debridement associated with Enamel matrix derivative gel (Emdogain, Straumann) |
| Open flap debridment | Active comparator | Procedure: Open flap debridementOpen flap debridement |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- diagnosis of chronic periodontitis
- presence of at least one pair of interproximal infrabony defects (2-3 walls) adjacent to vital anterior or premolar teeth
- absence of 2 and 3 mobility degrees
- probing pocket depth (PPD)≥ 5mm
- full-mouth plaque score ≤ 20%
Key exclusion criteria (3 listed)
- presence of any systemic disease that could interfere with periodontal treatment
- infrabony defects with trans-surgical depth ≤4mm
- antibiotic treatment administered during the last 6 months -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| enamel matrix derivativeAlso: Emdogain, StraumannOpen flap debridement associated with enamel matrix derivative | Drug | enamel matrix derivative |
| Open flap debridementOpen flap debridement | Procedure or surgery | Open flap debridment, enamel matrix derivative |
Primary outcome
Distance from the cemento-enamel junction (CEJ) to the bottom of the defect (BD)
Time frame: 24 months
The most coronal area where the periodontal ligament maintained an even width was identified to measure the most apical extension of the infrabony defect
2 secondary outcomes
Distance from the CEJ to the bone crest
Time frame: 24 months
Infrabony defect angle
Time frame: 24 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jul 2014.
- Results publication: PubMed 20165744Chambrone D, Pasin IM, Chambrone L, Pannuti CM, Conde MC, Lima LA. Treatment of infrabony defects with or without enamel matrix proteins: a 24-month follow-up randomized pilot study. Quintessence Int. 2010 Feb;41(2):125-34.
- Results publication: PubMed 17710290Chambrone D, Pasin IM, Conde MC, Panutti C, Carneiro S, Lima LA. Effect of enamel matrix proteins on the treatment of intrabony defects: a split-mouth randomized controlled trial study. Braz Oral Res. 2007 Jul-Sep;21(3):241-6. doi: 10.1590/s1806-83242007000300009.
- Derived from this study: PubMed 25475143Ragghianti Zangrando MS, Chambrone D, Pasin IM, Conde MC, Pannuti CM, de Lima LA. Two-year randomized clinical trial of enamel matrix derivative treated infrabony defects: radiographic analysis. BMC Oral Health. 2014 Dec 4;14:149. doi: 10.1186/1472-6831-14-149.
Related trials for Chronic Periodontitis
Not yet recruiting
Clinical and Inflammatory Outcomes of Regenerative Endodontic Treatment Using Injectable Platelet-Rich Fibrin in Mature Necrotic Teeth With Chronic Apical Periodontitis.
Chronic Apical Periodontitis, Pulp Necrosis
Recruiting
Effect of Cyperus Articulatus on Bacterial Reduction and Postoperative Pain
Chronic Apical Periodontitis
RecruitingObservational study
Prevalence and Associated Factors of High BMI and Periodontitis in Thai Adults Aged Under 60 Years
Diabete Mellitus, Dyslipidaemia
RecruitingObservational study
Evaluation of Masticatory Performance in Patients With Periodontitis
Periodontitis, Adult, Periodontitis
Recruiting
Postoperative Pain and Success of Single-Visit Root Canal Treatment Using Different Root Canal Sealers in Asymptomatic Teeth
Single-visit, Periapical Periodontitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Luiz Antonio PA Lima, Associate principal investigator
University of Sao Paulo
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing enamel matrix derivative and Open flap debridement in people with Chronic Periodontitis, run by University of Sao Paulo at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Jul 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Distance from the cemento-enamel junction (CEJ) to the bottom of the defect (BD) (time frame: 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02195765, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jul 2014.